An ongoing Phase III clinical trial (JUNIPER) is evaluating the efficacy and safety of abemaciclib compared to erlotinib in previously treated patients with advanced KRAS-mutated NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.